Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported an open-market sale of common stock indirectly held through a trust. The filing shows the trust sold 23,145 shares at a weighted average price of $86.4201 per share, with individual trades executed between $86.27 and $86.57. After this transaction, the trust still holds 98,611 shares. Separate holding entries show 30,969.5756 shares held indirectly through a 401(k) plan and 22,798.2532 shares held directly, providing additional context on his overall ownership.
Form 144 filing reports multiple open-market sales of Common stock by Donald Bobo. The filing lists sales on 03/02/2026, 04/02/2026, 05/04/2026, 05/07/2026, 05/12/2026, and 05/15/2026 with per-trade share counts and proceeds. The document also lists earlier restricted stock vesting dates and grant totals under a registered plan for the issuer.
Edwards Lifesciences Corp executive Daveen Chopra, CVP, TMTT & Surgical, reported an open-market sale of 1,500 shares of common stock. The shares were sold at a weighted average price of $84.6035 per share in multiple trades between $84.6002 and $84.6050. Following this transaction, Chopra directly holds 44,324 shares of Edwards Lifesciences common stock.
Edwards Lifesciences Corporation submitted a notice related to the proposed sale of securities. The filing lists a Performance Stock Lapse of 1,359 shares with a 05/07/2023 date and a Restricted Stock Lapse of 141 shares with a 05/08/2023 date. The broker listed is Charles Schwab & Co., Inc.
Edwards Lifesciences Corp executive Daniel J. Lippis reported an option exercise and related share sale under a pre-planned Rule 10b5-1 trading plan. On 2026-05-18, he exercised employee stock options for 620 shares of common stock at an exercise price of $72.68 per share and sold 620 shares in an open-market transaction at $81.14 per share.
Following these transactions, Lippis directly held about 40,410.9103 shares of common stock and 6,190 employee stock options exercisable into common shares. Because the activity was executed pursuant to a Rule 10b5-1 plan adopted on February 13, 2026, the timing appears routine rather than discretionary.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported open-market sales of company common stock. On May 15, 2026, he sold 8,000 shares indirectly through a 401(k) account at $81.8216 per share and 9,968 shares directly at $82.0732 per share. A footnote notes the directly held sale was executed in multiple trades with prices ranging from $81.975 to $82.260, and the reported price is a weighted average. After these transactions, he held 22,798.2532 shares directly, 30,969.5756 shares indirectly via the 401(k), and 121,756 shares indirectly in a trust.
Edwards Lifesciences files a Form 144 reporting a proposed sale of common stock. The filing lists 150,758.00 (units shown) associated with Charles Schwab & Co., Inc. on 05/18/2026 with method noted as Broker Payment for Cashless Exercise. The filing also records four completed sales in the prior three months: 87,004, 82,523, 84,585 and 85,576 (dated 03/11/2026, 04/06/2026, 05/01/2026, and 05/04/2026 respectively).
Edwards Lifesciences reported proposed insider sales under Form 144. The filing lists multiple equity compensation-based disposals and notices of proposed sales dated 02/25/2026, 03/02/2026, and 04/02/2026 by Donald E. Bobo Jr., with share quantities and aggregate dollar amounts shown.
Edwards Lifesciences CEO Bernard J. Zovighian reported several stock transactions. On May 11, 2026, he exercised 47,207 Performance Rights into common stock, with 26,198 shares withheld at $79.96 per share to cover tax obligations, leaving him with additional net shares rather than an open-market sale. The filing notes these vested from performance-based restricted stock units granted in May 2023, after the board’s committee certified 167.70% of the target as earned.
On May 12, 2026, a trust associated with him sold a total of 36,351 common shares in open-market trades at weighted average prices around $78 per share, and there were two bona fide gifts totaling 53,280 shares between direct and trust holdings. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025. After the reported transactions, he holds about 99,165 shares directly, plus additional indirect holdings through a trust and a 401(k) plan.
Edwards Lifesciences Corp corporate officer Donald E. Bobo Jr. reported equity compensation activity tied to performance-based restricted stock units. On May 11, 2026, he exercised 13,457 Performance Rights, receiving the same number of shares of common stock.
To cover tax obligations, 7,469 common shares were withheld at $79.96 per share, a non-market disposition. After these transactions, he held 40,235.2532 common shares directly, plus 121,756 shares by trust and 38,969.5756 shares in a 401(k) indirectly. A prior grant from May 11, 2023 vested at 167.70% of its target following a three-year performance period, and the related Performance Rights now show 0 remaining, having been fully exercised.